Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association
Authors' conclusion
Anti-AGE and anti-MAA were present in around 45% of RA patients and 30% of non-RA arthritis patients, and although not specific for RA, their presence associated with HLA, inflammation and, for RA, with clinical outcomes especially in patients with seronegative RA.
Study context
- Population
- Patients from the Leiden Early Arthritis Clinic with rheumatoid arthritis (RA) and without RA
- Participants
- 648 vs 538
- Exposure
- RA vs non-RA arthritis
- RAn = 648
- Non-RAn = 538reference
- Outcome
- Prevalence of anti-AGE and anti-MAA IgG antibodies
Methodological detailsLeiden Early Arthritis Clinic, ELISA, regression, correlation and survival analyses
- Leiden Early Arthritis Clinic
- ELISA
- Regression, correlation and survival analyses
Main finding
As reported in the abstract
Prevalence of anti-AGE and anti-MAA
anti-AGE
anti-MAA
Observational data: associations, not effects.
Further findings
Association with HLA-DRB1*03 within seronegative RA
| OR | P value | |
|---|---|---|
| Anti-AGE | 1.98 | P = 0.003 |
| Anti-MAA | 2.37 | P < 0.001 |
| Outcome | OR | P value |
|---|---|---|
| Anti-AGE association with HLA-DRB1*03 in non-RA arthritis | 2.34 | P < 0.001 |
Anti-MAA and inflammation markers (ESR, CRP)
- Anti-MAA associated significantly with ESR and CRP in all groups, independent of anti-AGE
Radiological progression and sustained drug-free remission in seronegative RA
- Anti-AGE and anti-MAA associated with radiological progression, but not evidently with sustained drug-free remission
Original publication
Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association. RMD Open. Published 1 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →